Overview Gemcitabine and S-1 for Advanced Biliary Tract Cancer Status: Completed Trial end date: 2013-12-01 Target enrollment: Participant gender: Summary This study will conduct a phase II study of gemcitabine and S-1 as first-line chemotherapy in patient with advanced biliary tract cancer Phase: Phase 2 Details Lead Sponsor: Hallym University Medical CenterCollaborator: Jeil Pharmaceutical Co., Ltd.Treatments: Gemcitabine